We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+27.71%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$12.3M
Cap. Flow
-$21.1M
Cap. Flow %
-6.55%
Top 10 Hldgs %
61.66%
Holding
80
New
8
Increased
8
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$12.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.01M
3
DELL icon
Dell
DELL
+$4.09M
4
LRMR icon
Larimar Therapeutics
LRMR
+$3.47M
5
IMRX icon
Immuneering
IMRX
+$2.85M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$15.9M
2
NCDL icon
Nuveen Churchill Direct Lending
NCDL
+$15.2M
3
TEM
Tempus AI
TEM
+$5.09M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$5.08M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.7M

Sector Composition

Rank Sector Weight
1 Healthcare 56.77%
2 Financials 22.9%
3 Technology 12.32%
4 Consumer Discretionary 7.01%
5 Energy 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCDL icon
1
Nuveen Churchill Direct Lending
NCDL
$609M
$42.7M 13.24%
3,091,553
-948,000
-23% -$15.2M
OBDC icon
2
Blue Owl Capital
OBDC
$5.35B
$26.1M 8.11%
2,045,070
– –
ENGN icon
3
enGene Therapeutics
ENGN
$120M
$22.4M 6.95%
3,278,106
-450,000
-12% -$2.05M
LRMR icon
4
Larimar Therapeutics
LRMR
$377M
$18.9M 5.87%
5,853,040
+925,000
+19% +$3.47M
EVCM icon
5
EverCommerce
EVCM
$2.14B
$18.3M 5.67%
1,641,929
– –
HLLY icon
6
Holley
HLLY
$335M
$15.3M 4.74%
4,862,361
+750,000
+18% +$2.23M
ROIV icon
7
Roivant Sciences
ROIV
$23.6B
$15M 4.64%
+988,249
New +$12.2M
CGEM icon
8
Cullinan Oncology
CGEM
$1.06B
$14.9M 4.62%
2,510,972
+125,000
+5% +$915K
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.46B
$12.7M 3.94%
422,438
+167,200
+66% +$5.01M
CNDT icon
10
Conduent
CNDT
$253M
$12.5M 3.87%
4,456,848
– –
SGMT icon
11
Sagimet Biosciences
SGMT
$435M
$9.11M 2.83%
1,328,351
– –
CMPX icon
12
Compass Therapeutics
CMPX
$349M
$9.07M 2.82%
2,591,525
– –
DELL icon
13
Dell
DELL
$239B
$7.42M 2.3%
52,334
+31,486
+151% +$4.09M
CVEO icon
14
Civeo
CVEO
$356M
$7.3M 2.27%
317,411
– –
CNTX icon
15
Context Therapeutics
CNTX
$56.7M
$7.18M 2.23%
7,407,906
– –
AQST icon
16
Aquestive Therapeutics
AQST
$452M
$6.99M 2.17%
1,250,000
+330,000
+36% +$1.43M
IRON icon
17
Disc Medicine
IRON
$2.81B
$6.76M 2.1%
102,260
-20,000
-16% -$1.19M
RPTX
18
DELISTED
Repare Therapeutics
RPTX
$6.06M 1.88%
3,443,659
– –
PVLA
19
Palvella Therapeutics
PVLA
$2.05B
$5.97M 1.85%
95,259
-30,000
-24% -$1.34M
EYPT icon
20
EyePoint Inc
EYPT
$999M
$5.23M 1.62%
367,594
-195,000
-35% -$2.24M
KRRO icon
21
Korro Bio
KRRO
$145M
$5.03M 1.56%
105,000
-20,000
-16% -$444K
IMA
22
ImageneBio Inc
IMA
$63.4M
$4.41M 1.37%
540,924
+199,997
+59% +$2.65M
PLRX icon
23
Pliant Therapeutics
PLRX
$65M
$4.39M 1.36%
2,969,199
– –
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$4.11M 1.28%
169,450
-161,150
-49% -$2.86M
IMRX icon
25
Immuneering
IMRX
$262M
$3.85M 1.2%
+550,000
New +$2.85M
1
2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q3 2025 Portfolio in Review

As of Q3 2025, Blue Owl Capital Holdings held 80 positions worth $322M, up 4% from $310M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Blue Owl Capital Holdings withdrew a net $21.1M in Q3 2025, closing 8 positions and reducing 12 holdings. Its most notable exit was Tourmaline Bio, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 51% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in Roivant Sciences worth $15M.

  • Blue Owl Capital Holdings's largest Q3 2025 buy was Roivant Sciences: 988,249 shares worth $15M.
  • Blue Owl Capital Holdings added most to Ultragenyx Pharmaceutical in Q3 2025, an estimated $5.01M increase.
  • Blue Owl Capital Holdings's biggest Q3 2025 reduction was Nuveen Churchill Direct Lending, cutting an estimated $15.2M.
  • Blue Owl Capital Holdings fully exited Tourmaline Bio in Q3 2025, selling an estimated $15.9M.
  • Blue Owl Capital Holdings's ten largest holdings make up 62% of its $322M portfolio in Q3 2025.
  • Blue Owl Capital Holdings opened 8 new positions and closed 8 in Q3 2025.
  • Blue Owl Capital Holdings's portfolio value rose 4% quarter-over-quarter to $322M.

Based on Blue Owl Capital Holdings's 13F filing for Q3 2025, filed 12 Nov 2025.